Sugi Predict

Sugi Predict / Compounds / SCHEMBL4303994

SCHEMBL4303994

SCHEMBL4303994

N[C@H](CC(C(=O)O)C(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.62
▸ SLC1A1 P43005 5/20 0.56
▸ SLC1A3 P43003 5/20 0.54
▸ SLC1A2 P43004 5/20 0.54
▸ PTGS1 P23219 1/20 0.52
▸ SLC7A11 Q9UPY5 1/20 0.52
▸ ENPEP Q07075 1/20 0.52
▸ GRIK1 P39086 4/20 0.50
▸ GRIK2 Q13002 4/20 0.50
▸ GGT1 P19440 2/20 0.50
▸ GRM1 Q13255 1/20 0.50
▸ GRM2 Q14416 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39093 1.00 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL148584 1.00 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL445471 1.00 SLC7A5 (0.62) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
Glycine SCHEMBL10994359 0.89 SLC7A5 (0.52) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
Aspartic Acid SCHEMBL22557639 0.89 SLC7A5 (0.52) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
Serine SCHEMBL6827952 0.89 SLC1A1 (0.60) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
Alanine SCHEMBL10991017 0.89 SLC7A5 (0.65) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL600881 0.87 SLC7A5 (0.68) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL9545322 0.87 SLC7A5 (0.68) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1
SCHEMBL29024969 0.87 SLC7A5 (0.68) SLC7A5SLC1A1SLC1A3SLC1A2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118829648-A P53 peptidomimetic macrocycles 默沙东有限责任公司 2024-10-22 — — CN claimed
EP-4444740-A2 P53 PEPTIDOMIMETIC MACROCYCLES Merck Sharp & Dohme LLC (US) 2024-10-16 — — EP claimed
CN-113627239-B Remote driving vehicle track prediction method combining lane change intention of driver 上海交通大学 2024-07-09 — — CN claimed
WO-2023107353-A2 P53 PEPTIDOMIMETIC MACROCYCLES MERCK SHARP & DOHME LLC (US) 2023-06-15 — — WO claimed
CN-112723528-B Ecological floating raft for marine environment restoration and restoration method 浙江海洋大学 2023-02-17 — — CN claimed
WO-2004026896-A2 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2004-04-01 — — WO claimed
US-6624290-B2 Modulating the activity of serine proteases SCHERING CORPORATION 2003-09-23 — — US claimed
US-20020103135-A1 Azapeptides useful in the treatment of Hepatitis C SCHERING CORPORATION 2002-08-01 — — US claimed
WO-2001058929-A1 AZAPEPTIDES USEFUL IN THE TREATMENT OF HEPATITIS C SCHERING CORPORATION (US) 2001-08-16 — — WO claimed
US-20260115334-A1 CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY PURDUE RESEARCH FOUNDATION (US) 2026-04-30 — — US disclosed
US-12397060-B2 pHLIP®-mediated intracellular delivery of immuno-stimulatory compounds UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2025-08-26 — — US disclosed
US-12290575-B2 Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2025-05-06 — — US disclosed
WO-2025079064-A1 INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS PEPTICOM LTD. (IL) 2025-04-17 — — WO disclosed
EP-4144368-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 — — US disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 — — US disclosed
WO-2004026896-A2 HCV NS-3 SERINE PROTEASE INHIBITORS MEDIVIR AB (SE) 2004-04-01 — — WO disclosed
US-6624290-B2 Modulating the activity of serine proteases SCHERING CORPORATION 2003-09-23 — — US disclosed
US-20020103135-A1 Azapeptides useful in the treatment of Hepatitis C SCHERING CORPORATION 2002-08-01 — — US disclosed
WO-2001058929-A1 AZAPEPTIDES USEFUL IN THE TREATMENT OF HEPATITIS C SCHERING CORPORATION (US) 2001-08-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115334-A1 CONJUGATES, COMPOSITIONS, AND METHODS FOR HYDROXYAPATITE-TARGETED IMAGING AND THERAPY FGF23, FOLH1, HDGF SLC7A5 44/4885SLC1A1 98/4885SLC1A3 79/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD SLC7A5 101/4885SLC1A1 186/4885SLC1A3 172/4885
US-20020103135-A1 Azapeptides useful in the treatment of Hepatitis C ENPEP, VIP, HAVCR2 SLC7A5 2677/4885SLC1A1 2512/4885SLC1A3 2286/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH SLC7A5 113/4885SLC1A1 213/4885SLC1A3 198/4885
US-12397060-B2 pHLIP®-mediated intracellular delivery of immuno-stimulatory compounds STING1, MAVS, IRF3 SLC7A5 1847/4885SLC1A1 4350/4885SLC1A3 3883/4885
US-12290575-B2 Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide NPPA, LNPEP, VIP SLC7A5 1516/4885SLC1A1 2117/4885SLC1A3 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.